Due to the pluripotent roles of CD276 in HNSCC pathogenesis, and since CD276 is a predictor for the responses to immunotherapy in HNSCC [20], the combined efficacies of anti-PD-1 and anti-CD276 targeting have been tested in advanced HNSCC [28]. The gene discussed is CD276; the disease is head and neck squamous cell carcinoma.